Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

Questions about the COVID-19 shot abound as federal recommendations shift and medical groups issue clashing guidance.

Combined with the administration’s erratic regulation and policymaking, it threatens to undo the salutary ecosystem that made ...

GSK (GSK) announced on Friday that the U.S. Food and Drug Administration (FDA) has approved a label expansion for its Arexvy vaccine against the Respiratory Syncytial Virus (RSV) to allow its use for ...

March 13 (Reuters) - British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age range for its respiratory syncytial virus vaccine, Arexvy, to include ...

GSK said the Food and Drug Administration expanded the approved age indication of its RSV vaccine to adults between the ages of 18 and 49 with increased risk of lower respiratory tract disease.

Food and Drug Administration (FDA) Commissioner Marty Makary on Friday announced that the agency’s top regulator Vinay Prasad ...